Post-earnings recap
Reported
Tue, May 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Regeneron Pharmaceuticals faced challenges this quarter, resulting in a significant EPS miss. The stock reacted negatively, dropping 6.34%. Investors are likely concerned about the company's ability to meet future earnings expectations without updated guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.45 | N/A | -23.47% |
Management expressed concerns about current market conditions impacting earnings. They remain committed to long-term growth through research and development.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing investments in R&D despite the EPS miss.